Beleaguered Medical Device Manufacturer Boston Scientific Announces Job Cuts

Things are just not going well for Natick, MA-based device manufacturer Boston Scientific. Yesterday, the company announced that it lost $1.1 billion in the fourth quarter this year. The losses mainly stem from the company’s $1.73 billion settlement earlier this month with Johnson & Johnson ending a seven year patent dispute over drug-coated cardiovascular stents. Also, Boston Scientifics’ ill-advised purchase of medical device rival Guidant for $27 billion several years ago hasn’t helped matters.

The company said that it would cut as many as 1,300 jobs or 8 to 10 percent of its workforce to reduce operating expenses. Boston Scientifics’ decision to eliminate jobs follows similar moves made by several of its competitors last year. For example, last spring Medtronic, the largest device firm in the world, said it would eliminate at least 1,500 workers. In August, Minnesota rival St. Jude Medical eliminated 200 positions.

Device makers have seen their sales squeezed by safety recalls of top-selling products and cost cutting measures at hospitals because of the economic downturn. Also, new data suggest that drug-coated stents may not offer the benefits (over bare-metal stents) as previously thought. In fact, some physicians are beginning to reconsider the advantages of stents as compared with other surgical or pharmacologic interventions for certain cardiac patients.

While layoffs at medical devices manufacturers don’t come close to the massive layoffs in the pharmaceutical sector, don’t be surprised if other device manufacturers announce layoffs later this year.

Until next time...

Good Luck and Good Job Hunting!!!!!!!!

 

Pharma Downsizing Spills Over to a Medical Devices Manufacturer

Minnesota-based Medtronic, Inc., one of the world’s largest medical devices companies, announced  that it was cutting about 1,100 jobs; 350 of which will be in Minnesota. This is the first layoff at the medical devices manufacturer in over 5 years. According to a press release, slightly over a third of the layoffs will come from the company’s local operations, which has about 8,000 employees. The overall effect of the reorganization will be relatively small—affecting roughly 3% of the company’s worldwide workforce of 39, 500.

Medtronic attributes the realignment (not restructuring according to company executives) to slumping sales of its spinal and cardiac devices. Accordingly, the company’s cardiac rhythm and neuroscience businesses along with local operations will bear the brunt of the job cuts.

It looks as though the entire life sciences sector is under assault. Belt yourself in—it’s going to be a rough ride for the foreseeable future!

Thanks to Ed at Pharmalot for the heads-up!

Until next time….

Good Luck and Good Job Hunting (are there any left?)!!!!!